The rates of brain-related diseases in Canada and the developed world are rising—not only among older adults, but also among those aged 18 to 45. In this younger group, the most common neurological disease is multiple sclerosis (MS). Unfortunately, current treatments target the immune system and have little or no effect on the brain.
Dr. Craig Moore, Canada Research Chair in Neuroscience and Brain Repair, is investigating how new biomarkers and drug targets can drive the brain’s own repair process. He and his research team are studying how specific genes contribute to brain injury and repair processes in patients with MS. Their work could lead to insights into a variety of brain conditions, including MS, Alzheimer’s, stroke, cancer and more. Ultimately, they hope to translate their findings into clinical practice to benefit patients and reduce the burden on both caregivers and Canada’s health care systems.